2542. Skin/Soft Tissue Infection Strategy Trials: What We Have Learned and What We Still Need to Know
Session: Symposium: Strategy Trials: A New Paradigm in Infectious Diseases Research
Saturday, October 6, 2018: 2:25 PM
Room: W 2005-2024
Loren Miller, MD, MPH, Medicine, David Geffen School of Medicine at University of California, Los Angeles., Los Angeles, CA

Loren Miller, MD, MPH is a Professor of Medicine at the David Geffen School of Medicine at University of California, Los Angeles. Dr. Miller also is the Associate Chief in the Division of Adult Infectious Diseases at Harbor-UCLA Medical Center where he is involved in patient care and education of students, residents, and fellows. He has served as the Director of the Infection Control Program at Harbor-UCLA for 8 years. Besides completing a fellowship in Infectious Diseases, he has also completed a fellowship in Health Services Research. His research interests include clinical outcomes, epidemiology, and molecular epidemiology of community-associated methicillin-resistant Staphylococcus aureus (CA-MRSA) infections and skin infections, urinary tract infections, HIV infection, and hepatitis. He has been the Principal Investigator or Co-Investigator on many investigations and clinical trials sponsored by the National Institutes of Health (NIH), Centers for Disease Control and Prevention (CDC), Agency for Healthcare Research and Quality (AHRQ), and other government-sponsored research agencies. Dr. Miller has authored over 100 manuscripts in peer-reviewed journals on a broad range of Infectious Disease and Internal Medicine related topics. His research focus is on common community and healthcare related infections such as methicillin resistant Staphylococcus aureus (MRSA). He is the Director of the Harbor-UCLA Infectious Diseases Clinical Outcomes REsearch Unit (ID-CORE), which has enrolled including over 1000 patients in the past 10 years into clinical trials. He has expertise in data collection and survey development, clinical trials, and data management of large clinical studies, and data analysis.


Disclosures:

L. Miller, Merck: Grant Investigator , Research grant . Achaeogen: Grant Investigator , Research grant . Genentech: Grant Investigator , Research grant .

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.